Sepsis Clinical Trial
Official title:
Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age (Inclusive) With Clinical or Confirmed Late-onset Sepsis : a European Multicenter Randomised Phase III Trial
This phase III multicentric international randomized trial is designed to compare the
efficacy of Meropenem to the standard of care in infants below 90 days of age with clinical
or confirmed late-onset sepsis (LOS).
The aim is to assess efficacy , pharmacokinetics and safety of Meropenem which are not well
known and documented in this population.
The principal objective is to compare the efficacy at test of cure (TOC) visit of meropenem
to the standard of care (SOC) in the treatment of clinical or confirmed LOS in infants ≤ 90
days of postnatal age.
The secondary objectives are:
- To compare the safety profile of meropenem to SOC
- To compare the efficacy at TOC visit of meropenem to SOC in confirmed sepsis
- To compare the response to meropenem and SOC on day 3 of antibacterial therapy
- To compare the efficacy at TOC visit of meropenem to SOC ignoring the change of
antibiotic(s) for safety reasons
- To compare the efficacy at TOC visit of meropenem to SOC by SOC regimen
- To compare survival at follow up (FU) visit (28 day visit) in the meropenem arm and SOC
arm
- To compare new infections and relapses that occur between TOC and FU visits in
participants with a favourable outcome at TOC visit by treatment arm
- To define the organisms causing LOS
- To study antibacterial susceptibility of LOS-causing organisms and to describe clinical
and microbiological responses according to this
- To compare gut colonization by antibiotic resistant organisms after treatment with
meropenem or SOC
- To compare bacterial eradication by treatment arm
- To compare time to NICU discharge across the 2 arms
- To describe PK of meropenem in infants ≤ 90 days of postnatal age with LOS
- To evaluate genetic parameters that may affect response to therapy
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
| Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
| Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
| Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
| Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
| Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
| Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
| Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
| Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
| Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
| Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
| Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
| Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
| Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
| Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
| Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
| Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
| Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
| Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
| Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |